What are the most important upcoming clinical catalysts for APGE in 2026?

The most closely watched catalysts for APGE are clinical data readouts from its lead pipeline programs, which span Phase 1 and Phase 2 trials in atopic dermatitis and related inflammatory indications. Data packages from dose-finding and proof-of-concept cohorts represent binary events: positive results can materially re-rate the stock upward, while disappointing efficacy or safety signals can trigger sharp declines. Key milestones to monitor include interim or top-line results from ongoing Phase 2 studies, any IND filings or first-patient-dosed announcements for earlier-stage assets, and updates presented at major medical conferences such as the American Academy of Dermatology or the American Thoracic Society. Regulatory interactions, particularly end-of-Phase-2 meetings with the FDA, also carry significant informational weight. Because exact timing windows for data releases shift with enrollment pace and protocol amendments, traders should cross-reference the company's most recent 10-Q and investor day materials for the current catalyst schedule.

How much cash runway does Apogee Therapeutics have before it needs to raise more capital?

Precise runway figures require the most recent balance sheet data from Apogee's SEC filings (10-K or 10-Q), which report cash, cash equivalents, and marketable securities alongside quarterly operating cash outflows. As a clinical-stage company with no product revenue, APGE funds operations entirely through previously raised capital, making the cash position one of the most scrutinized line items in each quarterly report. A common analyst approach is to divide the reported cash balance by the trailing quarterly net cash used in operations to estimate remaining quarters of runway. Clinical-stage biotechs with multiple active trials typically burn between $30 million and $80 million or more per quarter depending on trial scope, so the implied runway can shift materially between reporting periods. If reported cash provides runway through several anticipated clinical readouts, that is generally viewed as a stronger balance sheet posture than a company that would need to raise capital before seeing meaningful data. Equity or debt offerings are a routine feature of the biotech lifecycle, but their impact on existing shareholders and CFD traders depends heavily on timing, dilution size, and market conditions at the time.

What is the difference between trading APGE stock and trading an APGE CFD on CoinUnited?

Buying APGE stock through a traditional brokerage gives you direct equity ownership: you receive voting rights, are subject to standard settlement cycles (typically T+2), and can only trade during U.S. equity market hours (9:30 a.m. to 4:00 p.m. Eastern, Monday through Friday). Gains and losses are realized only when you close the position. Trading an APGE CFD on CoinUnited means you are taking a position on the price movement of APGE shares without owning the underlying equity. There are no voting rights or settlement delays. A small move in the underlying price translates into a proportionally amplified gain or loss on the margin used. CoinUnited also keeps the APGE CFD available for trading 24 hours a day, 7 days a week. This is particularly relevant for biotech names, where major catalysts, FDA decisions, clinical data releases, or partnership announcements, frequently occur outside regular exchange hours. The ability to enter or exit a position immediately when news breaks, rather than waiting for the next market open, is a structural difference from traditional stock trading.

Why do clinical-stage biotech stocks like APGE move so dramatically on data readouts?

Clinical-stage biotechs carry what analysts call binary risk: before a drug is approved, the company's entire valuation is a probability-weighted estimate of a future that may or may not materialize. When a data readout arrives, it collapses that probability distribution, either confirming or disconfirming the thesis, and the stock reprices rapidly to reflect the new expected value. For a company like APGE with no approved products, a single Phase 2 readout can represent the difference between a credible path to commercialization and a pipeline that needs to be reconsidered entirely. Markets price this by assigning a probability of success before the event; when the actual result deviates from consensus expectations, the gap between the old probability-weighted price and the new one is realized instantly. This explains why single-day moves of 30%, 50%, or more in either direction are not unusual for clinical-stage names. For CFD traders, this volatility creates both opportunity and risk. Leverage amplifies both sides of the move, meaning a position sized without accounting for potential data volatility can produce losses that exceed the initial margin on a large adverse move. Position sizing relative to account equity is a key practical consideration when trading high-beta biotech CFDs.

Who are the main institutional holders of APGE and what does insider ownership look like?

Institutional ownership composition for APGE can be found in 13F filings aggregated through sources such as SEC EDGAR, FactSet, or Bloomberg's ownership function. Clinical-stage biotechs of this profile typically attract a mix of dedicated healthcare and biotech fund managers, crossover investors who participated in pre-IPO rounds, and index funds with broad small- or mid-cap mandates. Insider ownership, held by founders, executives, and board members, is disclosed in proxy statements (DEF 14A) and Forms 4 filed with the SEC whenever insiders buy or sell. High insider ownership relative to the float is sometimes interpreted as a signal of management conviction, while significant insider selling can attract scrutiny. The timing and size of insider transactions are publicly available and are tracked closely by institutional investors. Because APGE is a clinical-stage company, large institutional holders tend to be long-horizon specialist funds with the sector expertise to evaluate the underlying science. Any shift in a major holder's disclosed position, visible in quarterly 13F updates, can itself be a market-moving event for a smaller-capitalization name with relatively concentrated ownership.

How does APGE compare to peers in the immunology antibody space targeting conditions like atopic dermatitis?

The immunology antibody space targeting type 2 inflammatory conditions is actively competitive. Approved therapies from large biopharmaceutical companies targeting IL-4/IL-13 and related pathways have already established strong clinical and commercial benchmarks that any new entrant must credibly differentiate against. Clinical-stage companies, including APGE, are generally evaluated on whether their molecules offer a meaningful improvement, in dosing interval, formulation, efficacy in difficult-to-treat patient subgroups, or tolerability, rather than simply replicating existing data. Peer comparison typically involves examining trial design choices, patient population definitions, and endpoint selection alongside preliminary efficacy and safety signals. Companies like Alumis and other clinical-stage immunology specialists occupy a similar risk/reward profile to APGE in that their valuations are similarly dependent on unproven clinical hypotheses. Differences in target biology, antibody engineering approach, and stage of development create distinct risk profiles even within the same therapeutic area. For traders, the peer group matters because positive or negative data from one company in the same pathway can move the entire group. A strong readout from a competitor validating the biology can lift APGE; a disappointing result or a safety signal in the class can pressure it. Monitoring the full peer landscape, not just APGE's own calendar, is relevant for managing event-driven exposure.

What leverage level is appropriate when trading a high-volatility biotech CFD like APGE?

This is a risk management question with no single correct answer, and nothing here constitutes financial advice. CoinUnited offers up to 1000x leverage on APGE CFDs, but the appropriate level for any individual account depends entirely on that account's size, risk tolerance, and the specific scenario being traded. As a reference point: clinical-stage biotechs can move 30-70% or more in a single session on data readouts. At 1000x leverage, a 0.1% adverse move against a fully leveraged position would eliminate the entire margin. At more conservative leverage, say 5x or 10x on a hypothetical $1,000 margin deposit, the same 0.1% move produces a much smaller proportional loss relative to the margin used, and the position survives normal intraday volatility. Higher leverage ratios are mechanically suited to very short-duration trades where the trader has a specific near-term catalyst thesis and a clearly defined exit. The key practical discipline is defining the maximum acceptable loss in dollar terms before opening a position, then working backward to determine the position size and leverage ratio consistent with that limit. The availability of 1000x leverage is a feature of the platform; how much of it to deploy on a given trade is a decision that sits entirely with the trader and their risk framework.

Does APGE pay dividends, and how is that handled on a CoinUnited CFD?

Apogee Therapeutics does not currently pay a cash dividend, which is typical for a clinical-stage biotech that is deploying capital entirely into R&D and pipeline development. Because APGE retains all cash rather than distributing it to shareholders, CFD holders on CoinUnited are not subject to dividend adjustment deductions that would otherwise reduce a long CFD position's value on an ex-dividend date. Should the company's dividend policy ever change in the future, CoinUnited would reflect any declared dividend as a cash adjustment to open CFD positions rather than delivering actual shares or cash distributions, consistent with standard CFD mechanics. For now, the absence of dividends means this particular variable does not affect the cost of holding an APGE CFD position.

Does APGE have a meaningful P/E ratio, and what valuation metrics actually apply to it?

APGE does not have a meaningful price-to-earnings ratio because the company is pre-revenue and reports net losses, making P/E undefined or negative in practical terms. For clinical-stage biotechs like Apogee, analysts typically focus on alternative frameworks: cash runway relative to upcoming catalysts, pipeline risk-adjusted net present value (rNPV) models, and comparisons to precedent licensing or acquisition transactions in the immunology antibody space. Market capitalization relative to cash on hand is another reference point, since it implies what the market is pricing for the pipeline beyond the existing balance sheet. These metrics reflect the speculative, optionality-driven nature of APGE's valuation rather than any current earnings power.

What does APGE's balance sheet look like, and does the company carry significant debt?

Apogee Therapeutics is a cash-funded, equity-financed company that raised capital through its 2023 IPO and subsequent offerings, and it does not carry the kind of commercial debt load typical of revenue-generating companies. The balance sheet is primarily composed of cash and short-term investments on the asset side, with liabilities mainly from operating expenses and payables rather than long-term debt obligations. This structure is common among clinical-stage biotechs and means the primary financial risk is cash consumption rate rather than debt-servicing pressure. For CFD traders, a debt-light balance sheet reduces the risk of a distressed financing event triggered by covenant breaches, though dilutive equity raises remain a recurring consideration for the sector.

How does APGE typically behave around earnings announcement dates?

Because APGE generates no product revenue, its quarterly earnings releases are less about profit-and-loss surprises and more about cash balance updates, operating expense guidance, and any pipeline commentary. Price volatility around earnings dates can still be meaningful if management provides new clinical timelines, updates R&D spending guidance, or discloses changes to the cash runway outlook. Traders should also note that options activity and short interest ahead of earnings can amplify intraday moves.

What is gap risk for APGE, and how does weekend or after-hours trading affect a CFD position?

Gap risk for APGE refers to the possibility that the stock's price opens significantly higher or lower than its previous close following a period when the underlying exchange was closed, typically overnight or over a weekend. Clinical-stage biotechs are particularly prone to gaps because material news — conference presentations, FDA correspondence, peer company data, or partnership announcements — can emerge at any time. On CoinUnited, the APGE CFD trades 24 hours a day, seven days a week, which means CFD pricing can adjust in real time to reflect developing news even while the Nasdaq is closed. However, during extended-hours periods, liquidity may differ from regular-session conditions, and spreads can widen, so position sizing during off-hours warrants consideration.

What is basis risk when trading an APGE CFD versus buying the stock directly on Nasdaq?

Basis risk in this context is the possibility that the CoinUnited APGE CFD price temporarily diverges from the underlying Nasdaq-listed share price. For liquid US-listed equities, CFD prices are typically derived directly from the exchange price and track it closely during normal market hours. During pre-market, after-hours, or weekend sessions — when the Nasdaq is closed — the CFD may incorporate available information such as futures markets, peer moves, or breaking news, while the official exchange price remains static at its prior close. This creates a transient basis that resolves when the Nasdaq reopens. The practical implication is that a CFD position's mark-to-market value during off-hours reflects CoinUnited's derived price rather than an executable Nasdaq quote.

How does leverage and liquidation work specifically for an APGE CFD position?

When trading an APGE CFD with leverage on CoinUnited, a trader controls a larger notional position than the margin deposited. For example, using 5x leverage on a $1,000 margin deposit would provide $5,000 of notional APGE exposure. If the position moves adversely by the margin percentage, the account approaches a liquidation threshold, at which point the platform may close the position to prevent the account balance from going negative. For a volatile clinical-stage stock like APGE, which can move 20–50% or more on a single data readout, the distance between entry price and a liquidation level can be crossed rapidly.

Can traders outside the United States access APGE CFDs on CoinUnited?

CoinUnited offers APGE as a CFD instrument, which means price exposure to the stock is available to eligible users globally without the need to open a US brokerage account or comply with US equity purchase regulations. Availability does depend on a user's jurisdiction, as certain countries restrict CFD trading or require local licensing. Users should verify their local regulations before opening a position. The CFD structure also sidesteps some of the administrative requirements associated with holding US-listed foreign securities, such as W-8BEN withholding on dividends, though since APGE pays no dividend, this is a moot point currently.

How does short selling work for APGE on CoinUnited, and are there any borrowing constraints?

On CoinUnited, traders can open a short CFD position on APGE without needing to locate or borrow shares, which is a requirement in traditional equity short selling. This is because a CFD is a contract for the price difference, not a transaction in the underlying shares. There are no hard-to-borrow fees or recalls that affect traditional short sellers in illiquid or heavily shorted stocks. For APGE, which can experience elevated short interest around catalyst events, this is a meaningful structural difference. The cost of holding a short CFD position is reflected in overnight financing rates rather than stock borrow fees. Leverage applies equally to short positions, so the same liquidation risk mechanics described for long positions apply in reverse for shorts.

What role does short interest play in APGE's price behavior during catalyst events?

Short interest in APGE reflects the proportion of shares sold short by market participants who expect the price to decline. When a positive clinical readout or partnership announcement occurs unexpectedly, heavily shorted stocks can experience a short squeeze, where short sellers rush to cover positions simultaneously, amplifying the upside price move beyond what fundamentals alone might justify. Conversely, high short interest can indicate institutional skepticism about near-term catalysts or general sector-level bearishness. The degree of short interest relative to average daily volume — the short interest ratio — determines how many trading days it would theoretically take for shorts to cover, with higher ratios indicating greater potential squeeze intensity. These dynamics are relevant for both equity holders and CFD traders given their direct price exposure.

How are APGE's clinical programs structured in terms of regulatory pathway and phase progression?

Apogee Therapeutics is advancing antibody candidates across multiple clinical phases, with programs targeting immunological pathways relevant to conditions such as atopic dermatitis and asthma. The regulatory pathway for these assets runs through the FDA's standard IND and NDA/BLA process, or equivalent agencies internationally, with phase 1 primarily assessing safety and dosing, phase 2 evaluating efficacy signals in defined patient populations, and phase 3 providing the pivotal evidence required for approval. Each phase transition requires regulatory clearance and is accompanied by data disclosures that function as discrete binary events for the stock. The company's design choices — such as subcutaneous formulations or extended dosing intervals — are positioned to address convenience and compliance factors that regulators and commercial partners consider in the competitive immunology market.

What macroeconomic or sector-wide factors can move APGE's price independent of its own pipeline news?

APGE's price is influenced by broader biotech sector sentiment in addition to its own clinical progress. Changes in US interest rate expectations affect how investors discount the future cash flows of early-stage growth companies, with rising rates generally compressing valuations for pre-revenue biotechs. FDA policy developments, such as changes to accelerated approval pathways or shifts in the agency's approach to immunology indications, can reprice the entire sector. Competitor data from other companies working on similar IL-13, IL-4, or IgE pathway programs can either validate or undermine the scientific thesis supporting APGE's approach. Index rebalancing events, broad risk-off market moves, and healthcare policy debates in the US Congress can also create price movements in APGE that are unrelated to the company's own pipeline milestones.

Naviger til andre kryptovalutaer

APGEApogee Therapeutics, Inc.

Hurtiglenker

Posisjonskalkulator

Posisjonsstørrelse (USD)Giring

Margin kreves

$10.00

P&L hvis APGE beveger seg

+1%+$10.00

+5%+$50.00

+10%+$100.00

Start handel med {leverage}x giring

Apogee Therapeutics, Inc.

APGE

$135.09

+0.00% (24h)

AksjerNivå COmsettelig på CoinUnited.io1000x giring

Today's SignalNext earnings2026-11-09Last earnings move0.0%2026-08-10Net income$-86MQ2 2026

How can you trade Apogee Therapeutics, Inc.? Apogee Therapeutics, Inc. (APGE) is publicly listed. On CoinUnited, eligible users can trade a APGE stock CFD — price exposure that tracks the share price. It is a price CFD, not equity (no shareholder voting; dividends reflected as an adjustment) — with extended / 24-hour trading and leverage, from US$100. Access terms vary by jurisdiction and product eligibility.

How to trade it

Trading stock CFDs on CoinUnited + strategy

Handelsregime Status

Giring

1000x

(Maks på CoinUnited.io)

Volatilitet

Lav

(0.00% 24h)

How the APGE CFD works

Before you trade, understand exactly what you get, what you don't, and where the risk sits.

What you buy

Price exposure to the APGE reference (a synthetic CFD) that tracks the CoinUnited reference up and down.

What you do NOT get

It is not equity: no shares, no voting rights; dividends are reflected as an adjustment, not paid to you.

Basis / session risk

The CoinUnited reference tracks the share price but can differ from the exchange price; extended-hours liquidity is thinner.

Leverage illustration: with $100 margin at 1000× leverage you open a $100,000 notional position; if price moves against you to the liquidation level the position is force-closed. High leverage magnifies both profit and liquidation risk.

Trading conditions on CoinUnited

Fee schedule as of 2026-08-19

Product type	CFD	Synthetic price exposure. You do not hold the underlying asset.
Trading fee	0,070%	Per side, at the standard tier. Falls with 30-day volume and reaches 0.000% at VIP 9.
Trading hours	Market session	Follows the market session and is closed at weekends and on market holidays.
Giring – intradag	1 000x	I aktive handelstimer. Krever 0,050% margin ved minste posisjonsstørrelse. Tilgjengelighet og maksimalnivå avhenger av produkt, jurisdiksjon og kontoens kvalifisering; giring forsterker tapene, og posisjoner kan bli likvidert.
Giring – over natten	10x	For posisjoner som holdes utover handelsdagen. Krever 5,000% margin ved minste posisjonsstørrelse.
Giring – helger og helligdager	10x	For posisjoner som holdes gjennom en markedsstengning. Krever 5,000% margin ved minste posisjonsstørrelse – sjekk posisjonsstørrelsen din før du tar den med inn i helgen.
Direction	Long or short	Take a position in either direction. A short position profits when the price falls and loses when it rises.
Funding	Crypto deposit	Fund and withdraw in crypto. No bank transfer or card is required.

See the full fee schedule →

Trading APGE CFDs on CoinUnited.io: Conditions, Strategy, and Risk Management

Understanding how those structural features interact with APGE's specific risk profile is essential before sizing any position.

Platform Mechanics for APGE

The underlying APGE shares list on NASDAQ with standard US cash-session hours: 9:30 a.m. to 4:00 p.m. Eastern Time, Monday through Friday, excluding US public holidays. The CoinUnited CFD carries no such restriction. It trades continuously through weekends, overnight sessions, and Asian business hours. For a name like APGE, that distinction is not academic.

Clinical-stage biotech announcements, trial readouts, FDA correspondence, partnership disclosures, and acquisition headlines, routinely arrive outside regular market hours.

In June 2025, the Financial Times reported that AbbVie was nearing a roughly $10.9 billion cash acquisition of Apogee, implying a premium of approximately 60% to Apogee's then-current valuation, according to Investing.com's coverage of a concurrent JPMorgan note.

A headline of that magnitude released on a Friday evening or over a weekend would leave traders on traditional brokerages unable to act until Monday's open. On CoinUnited, the CFD remains executable the moment information enters the market.

Catalyst-Window Strategy

For APGE specifically, catalyst-window positioning is the primary strategic framework. The company's value is concentrated in a small number of clinical programs, with zumilokibart (APG777) as the lead asset. According to JPMorgan analysts cited by Investing.com in June 2025, zumilokibart was expected to enter Phase 3 trials in the coming months following its Phase 2 work in atopic dermatitis.

Transitions between trial phases, and interim data releases from those trials, represent discrete binary events that can move the stock sharply in a single session.

Traders monitoring APGE for catalyst-driven positioning should track: the company's investor relations calendar for anticipated data windows; major healthcare and dermatology conferences including JPMorgan Healthcare, ASCO, and AAD where pipeline updates are commonly presented; and SEC filings (Form 8-K) that disclose material clinical or corporate developments.

As of June 2026, publicly tracked APGE call option activity at the June 2026 expiry was visible on options-chain data services, per Futubull's public options tracking page, elevated options interest at specific strikes can signal market consensus around an anticipated catalyst window.

Leverage Calibration for a High-Volatility Biotech

While CoinUnited supports up to 1000x leverage on APGE, the structural volatility of clinical-stage biotech requires that effective leverage be calibrated well below that maximum for risk-controlled positions.

Single-session moves of 30–70% on binary data readouts are within the documented range for this asset class, and APGE's acquisition-related trading history, including the roughly 60% implied premium cited in Financial Times reporting, illustrates the magnitude of gap moves that can occur.

The correct sizing method begins with maximum acceptable loss, not maximum available exposure:

Parameter	Example
Account capital	$1,000
Max acceptable loss per trade	2% ($20)
Anticipated stop distance (e.g., 15% from entry)	15%
Implied position size	$20 ÷ 0.15 = $133 notional
Effective leverage used	$133 ÷ $1,000 = ~0.13x account

In this example, a trader with $1,000 in capital limiting loss to $20 with a 15% stop uses roughly $133 in notional exposure, far below what 1000x leverage would theoretically permit. The platform maximum represents a ceiling, not a target.

Gap Risk and the 24/7 Mitigation

Gap risk is the defining technical hazard for leveraged biotech CFDs. A negative Phase 2 readout released after the Friday close can produce a Monday open that gaps well beyond any stop placed at the prior close price, leaving a highly leveraged position exposed to a loss larger than the margin posted.

That window does not eliminate gap risk entirely, price discovery in low-liquidity overnight periods can be uneven, but it restores some agency that traditional brokerages remove entirely.

For context on the broader macro and sector environment affecting biotech valuations, interest rate sensitivity of long-duration growth assets, and institutional risk appetite relevant to positioning decisions, the 2026 Stocks Market Outlook provides current equity market analysis.

Pre-Trade Checklist for APGE CFD Positions

-Confirm whether a known catalyst window (trial readout, conference presentation, FDA interaction deadline) falls within or near the intended holding period.
-Set stop-loss levels before entry; size the position from that stop distance and maximum acceptable dollar loss.
-Account for the possibility that price gaps through the stop on binary events; size accordingly.
-Monitor APGE SEC filings (Form 8-K) and the investor relations calendar for unscheduled disclosures.

⚡1000x💰0% Fee⏱️10s Start🌐24/7

Klar til å handle APGE?

Opptil 1000x giring

Handle APGE nå

Key facts & how to trade

The essentials + how you access it on CoinUnited

Access & Tradability Comparison

A CoinUnited stock CFD vs holding the underlying shares — how, when, and in what form you get exposure. The stock price is everywhere; this comparison is the differentiator.

Terms	CoinUnited (CFD)	Holding shares (exchange)
Product form	Stock CFD (price exposure)	Equity ownership
Trading hours	Extended / 24h (by product)	Exchange regular hours
Leverage	Available (by product terms)	None / margin account needed
Shareholder rights	None (no voting; dividends as adjustment)	Voting + dividends
Access	Eligible users, by region + product	Brokerage account required

*Access and minimum vary by jurisdiction and product eligibility.

Nøkkelfakta

De mest siterte opplysningene om dette selskapet, hver med sin kilde - hurtigreferansen for lesere og AI-svarmotorer.

Noteringsstatus	Børsnotert: APGEExchange
52-ukers intervall	$130.34 – $232.80CoinUnited daily kline
Neste rapport	2026-11-09Finnhub
Kursreaksjon på siste rapport	+0.0% (1d), -0.0% (5d) — 2026-08-10CoinUnited daily kline
CoinUnited-produkt	Aksje-CFD - kun priseksponering, ikke aksjer (ingen stemmerett; utbytte gjenspeiles som justeringer); giring er tilgjengelig, utvidede handelstider / 24 t.CoinUnited product terms

Pris & Markedsstruktur

24H Område: $135.09→$135.09

24H Lav

$135.09

24H Høy

$135.09

BID / ASK

$135.02 / $135.16

Laster diagram...

Company & financials

Business model + audited SEC financials

What Is Apogee Therapeutics (APGE)?

TL;DR

Apogee Therapeutics is a clinical-stage antibody-focused biotech whose valuation is driven almost entirely by pipeline readouts, balance sheet runway, and probability-adjusted peak-sales estimates across immune and inflammatory disease indications.

Apogee Therapeutics, Inc. (NASDAQ: APGE) is a clinical-stage biotechnology company developing differentiated, extended half-life antibody therapies for inflammatory and immunology (I&I) diseases. Incorporated in 2022 and headquartered in Waltham, Massachusetts, according to the company's 2024 Form 10-K filed with the SEC, Apogee has no approved commercial products as of mid-2026.

Its value resides entirely in its pipeline of biologic programs and the probability that those programs will reach regulatory approval.

Business Model and Financial Structure

Apogee's business model is research and development-centric. The company generates minimal or no product revenue; operations are funded through equity raises and strategic financing arrangements rather than commercial sales. Standard revenue-based valuation multiples, price-to-sales, EV/EBITDA, do not apply in the conventional sense.

Analysts instead model each pipeline program as a discrete risk-adjusted asset, applying probability-weighted net present value (NPV) methods to estimate the contribution of each asset to total enterprise value.

The primary balance-sheet metric for a company at this stage is cash and marketable securities, which determines how many quarters of operations the company can fund before requiring additional capital. Secondary financial metrics drawn from SEC filings (Form 10-K and 10-Q) include R&D expense as a proportion of total operating costs and net loss per share.

These figures, rather than revenue growth rates, are the appropriate gauges of financial health for a pre-commercial biotech.

In May 2026, Apogee announced a $1.3 billion strategic financing collaboration with Blackstone Life Sciences to support Phase 3 development and potential commercialization of its lead asset, according to a company press release. Management described the arrangement as non-dilutive, designed to accelerate clinical development while limiting equity dilution to existing shareholders.

Pipeline Structure and Therapeutic Focus

According to Apogee Therapeutics' investor relations materials, the company's strategic focus is engineering long-acting antibodies for high-prevalence inflammatory diseases, targeting less frequent dosing schedules while aiming for best-in-class efficacy profiles. The pipeline is organized by asset and indication, each representing a separate risk-adjusted value component.

The lead program is Zumilokibart (APG777), a subcutaneous extended half-life monoclonal antibody targeting IL-13, being evaluated in the Phase 2 APEX trial for moderate-to-severe atopic dermatitis. In May 2026, Apogee reported positive 16-week Part B induction dose optimization results from that trial, positioning the program for Phase 3 planning, per the company's press release.

Beyond atopic dermatitis, the 2024 Form 10-K identifies additional programs: APG333, a subcutaneous extended half-life monoclonal antibody against TSLP for asthma and COPD; APG808, targeting IL-4Rα for type-2 allergic diseases; APG990, another subcutaneous extended half-life antibody for atopic dermatitis; and APG279, a preclinical atopic dermatitis program.

Each program targets type-2 inflammatory pathways, reflecting a concentrated therapeutic strategy within the I&I space.

Market Classification and Trading Characteristics

APGE trades on the NASDAQ exchange and is classified within the biotechnology sub-sector of healthcare. The stock falls into the smid-cap, high-beta category typical of clinical-stage companies.

For context on how biotechnology stocks behave within the broader 2026 Stocks Market Outlook, clinical-stage names exhibit structurally elevated price volatility relative to large-cap pharmaceutical peers.

Binary clinical readouts, regulatory interactions, and capital market conditions are the primary price drivers, not macroeconomic cycles or quarterly earnings beats.

Feature	Description
Exchange	NASDAQ (Ticker: APGE)
Company Stage	Clinical-stage, no approved products
Sector	Healthcare, Biotechnology
Market Cap Category	Smid-cap, high-beta
Primary Value Driver	Pipeline clinical outcomes and cash runway
Key Balance-Sheet Metric	Cash and marketable securities
Lead Asset	Zumilokibart (APG777), Phase 2 atopic dermatitis
Incorporated	2022, Waltham, Massachusetts

Sist oppdatert: 2026-06-22

Nøkkelinnsikter

APGE is a binary-event stock: individual clinical readouts or regulatory interactions can move the share price dramatically in a single session, making position-sizing discipline more important than directional conviction.
As a pre-revenue or early-revenue biotech, traditional valuation multiples (P/E, EV/EBITDA) are not applicable; cash runway, R&D burn rate, and risk-adjusted net present value of the pipeline are the relevant analytical frameworks.
The antibody therapeutics space in immunology and inflammation is highly competitive, with large-cap incumbents and well-funded peers pursuing overlapping targets, differentiation at the mechanism-of-action level is the key moat metric to monitor.
Institutional ownership concentration and insider activity (SEC Forms 3, 4, 5) are leading indicators of sentiment shifts for smid-cap biotechs like APGE, often signaling upcoming capital raises or partnership discussions before press releases.
Clinical-stage biotechs with strong management teams and clean balance sheets historically attract acquisition interest from large pharma, making APGE's cash position and data package a dual-purpose asset for both independent development and M&A optionality.

Key Financials

Audited · SEC filings

Reported figures from the company’s latest SEC filings — each linked to its source filing and period.

$-86M

Net income

Q2 2026 · SEC 10-Q

$-1.14

Diluted EPS

Q2 2026 · SEC 10-Q

Figures are from the company’s audited SEC filings; each carries its filing source and period. Not investment advice.

Machine-readable table — same figures, per-metric source

Metric	Value	Source
Net income (Q2 2026)	$-86M	SEC 10-Q
Diluted EPS (Q2 2026)	$-1.14	SEC 10-Q

APGE in Context: Competitive Landscape and Peer Comparison

Apogee Therapeutics competes in one of the most contested segments of clinical-stage biotechnology: Type-2 immunology, where well-capitalized incumbents and emerging challengers are pursuing the same mechanistic targets across atopic dermatitis, asthma, and related inflammatory indications.

As of June 2026, the competitive landscape and a reported acquisition approach from AbbVie together frame the clearest picture available of how the market is pricing APGE's relative position.

The Mechanistic Competitive Set

According to Apogee's Form 10-K filed with the SEC (March 2025) and Evaluate Vantage immunology pipeline commentary (February 2026), Apogee's pipeline concentrates on three mechanistic nodes: IL-13 (zumilokibart/APG777), TSLP (APG333), and IL-4Rα (APG808).

These targets directly overlap with the approved biologics that currently define the standard of care across dermatology and respiratory indications.

According to Evaluate Pharma's November 2025 atopic dermatitis landscape report, the primary competitive benchmarks for zumilokibart in atopic dermatitis include dupilumab (anti-IL-4Rα, Sanofi/Regeneron), lebrikizumab (anti-IL-13, Eli Lilly), tralokinumab (anti-IL-13, LEO Pharma), and amlitelimab (anti-OX40L, Sanofi).

In asthma and broader Type-2 inflammation, Evaluate Vantage's September 2025 asthma biologics review adds tezepelumab (anti-TSLP, Amgen/AstraZeneca), benralizumab, mepolizumab, and omalizumab to the reference set.

As one biopharma equity analyst observed in Evaluate Vantage's February 2026 immunology commentary:

> "With programs against IL-13, IL-4Rα and TSLP, Apogee is positioning itself as a focused Type-2 inflammation player competing at the same mechanistic nodes as established blockbusters like dupilumab and tezepelumab."

Direct head-to-head data between Apogee's assets and these approved agents does not yet exist; differentiation will ultimately be established in Phase 3 trials.

Efficacy Data as a Competitive Differentiator

For clinical-stage immunology companies, the quality of Phase 2 data is the primary input to peer-relative valuation. According to Apogee's May 2026 APEX Part B topline results press release filed with the SEC, zumilokibart's mid-dose regimen achieved EASI-75 in 65.9% of patients at week 16, compared with 23.4% on placebo.

The company selected this dose for advancement into Phase 3, planned to initiate in the second half of 2026.

Evaluate Vantage's November 2025 atopic dermatitis analysis described zumilokibart as part of a new generation of high-affinity, subcutaneous IL-13 antibodies that aim to raise the efficacy bar while maintaining convenient dosing relative to first-generation biologics.

The Phase 3 program will need to replicate and extend these results against a more demanding endpoint package before regulatory and commercial positioning can be confirmed.

M&A Comparables and Acquisition Premium Context

The most direct market signal on APGE's competitive value emerged in June 2026. According to a Financial Times report cited by Reuters, AbbVie is nearing an all-cash acquisition of Apogee Therapeutics at an implied valuation of approximately $10.9 billion. Reuters summarized the rationale as AbbVie seeking to reinforce its immunology franchise as Humira and Skyrizi face intensifying competition.

This reported transaction, if completed, would rank among the larger smid-cap immunology acquisitions and illustrates a structural feature of the sector: large pharmaceutical companies, including AbbVie, Sanofi, and AstraZeneca, have historically paid material premiums to pre-announcement market capitalization for clinical-stage immunology assets with credible Phase 2 data packages.

For a broader view of how acquisition dynamics are shaping biopharmaceutical valuations across the 2026 Stocks Market Outlook, sector context is relevant.

Calibrating Relative Valuation

Peer comparison in clinical-stage biotech requires matching on four dimensions simultaneously: pipeline stage, indication overlap, mechanistic differentiation, and cash position.

Simple market-cap ranking against larger entities such as Regeneron or AstraZeneca's biologics divisions provides limited signal; the more relevant reference set consists of companies at a comparable Phase 2-to-3 transition point with overlapping indication targets.

According to available data, APGE's precise market capitalization at any given moment is best drawn from a live terminal given the volatility typical of binary clinical events.

What the research context does confirm is that the combination of positive APEX Phase 2 data (May 2026), a Blackstone Life Sciences strategic financing arrangement announced in May 2026, and reported AbbVie acquisition interest (June 2026) represents a concentrated sequence of value-determining events that has materially affected how the sell-side weighs risk-adjusted pipeline value relative to

peers in the Type-2 immunology space.

Why Trade APGE? Catalysts, Risks, and the Bull-Bear Framework

Apogee Therapeutics represents a distinct category of trading instrument: a clinical-stage, single-platform biotech whose price is determined almost entirely by the probability-adjusted value of its pipeline rather than by earnings, revenue growth, or macro-cyclical factors.

As of June 2026, the AbbVie acquisition announcement has crystallized the bull case in a single transaction, but the preceding months offer a textbook illustration of how catalyst-driven repricing operates across the asset class, and why active traders benefit from understanding the underlying framework before the next comparable catalyst.

Tier One Catalysts: Clinical Data Readouts

Clinical data releases are the primary price driver for any pre-commercial biotech. The APEX trial sequence demonstrates this pattern clearly.

When Apogee reported 16-week Part B results for zumilokibart on May 27, 2026, the data were objectively positive: according to Apogee's SEC Form 8-K (via StockTitan), 65.9% of mid-dose patients achieved EASI-75 versus 23.4% on placebo, a 41.9% placebo-adjusted difference, meeting primary and secondary endpoints with high statistical significance.

Yet APGE fell approximately 11% in pre-market trading from around $81.16 to approximately $72.23, according to Tickeron's event recap. The explanation is expectations management. Heading into the event, the Street held a Buy consensus with an average 12-month price target of approximately $112, per Tickeron's summary of sell-side data.

When actual efficacy landed below the market's implied bar, the stock repriced downward despite a technically successful trial.

This dynamic, data that are good but not blockbuster producing a sell reaction, is among the most common traps in clinical biotech trading. Traders need to model both the absolute outcome (trial pass/fail) and the relative outcome (actual versus consensus expectation). The former is a binary, the latter is a continuous variable.

Tier Two Catalysts: Regulatory and Partnership Events

Regulatory interactions, including FDA Fast Track or Breakthrough Therapy designations, IND clearances, and clinical holds, represent a second catalyst tier. These events typically arrive with limited advance notice and can move a stock materially before regular session opens.

According to available data from the research context, specific FDA designation details for Apogee's programs were not publicly confirmed in accessible sources as of June 2026, but the structural risk remains present across all clinical-stage assets.

Partnership transactions constitute a related catalyst. Apogee's Blackstone Life Sciences collaboration, announced in mid-2025, was structured to fund zumilokibart development through potential commercialization in atopic dermatitis, asthma, and eosinophilic esophagitis, according to Apogee's press disclosure via StockTitan.

Such arrangements directly affect dilution risk, cash runway, and probability-of-success estimates, and each represents a discrete repricing event.

Tier Three Catalyst: Acquisition Premium

The AbbVie acquisition announced June 22, 2026 illustrates the maximum-magnitude event for a clinical-stage asset. AbbVie agreed to acquire Apogee for $10.9 billion, or $135.11 per share in cash, a roughly 49.5% premium to APGE's prior closing price of $90.38, with APGE shares spiking approximately 46% in pre-market trading, according to Tickeron's recap of the announcement.

For traders, this type of outcome highlights why clinical biotech positions carry asymmetric payoff profiles: confirmation of differentiated clinical data often precedes M&A interest from large-cap strategics.

Risk Framework

Four risk factors define the downside case for APGE-type instruments:

Risk Factor	Mechanism	APGE-Specific Illustration
Clinical failure	Trial misses primary endpoint; probability-of-success falls to near zero	APEX Part B beat endpoints, but a miss would have repriced sharply lower
Competitive displacement	Larger-cap peer achieves proof-of-concept first; addressable market share compresses	Dupixent (dupilumab) is the established standard; APG779 vs. Dupixent data pending in 2026 per Tickeron
Macro-driven sector de-rating	Rising rates compress long-duration growth multiples; biotech ETFs sell off	Affects all pre-revenue biotechs simultaneously; no company-specific hedge
Liquidity risk	Smid-cap names carry lower average daily volume; wide bid-ask spreads in stress	Pre-market moves of 11–46% illustrate the thinly traded window that matters most

The lock-up expiry coinciding with the May 2026 data release exemplifies how liquidity risk amplifies catalyst-driven moves. Selling pressure from insiders exiting alongside a data event produced a compounded drawdown beyond what the clinical result alone would have implied.

The Optionality Framework

Apogee does not fit a growth-versus-value classification. It is an optionality instrument: its price reflects the probability-weighted value of multiple future states, each contingent on binary or semi-binary clinical and regulatory outcomes.

As Apogee management noted at the Goldman Sachs 47th Annual Global Healthcare Conference 2026, zumilokibart's Phase 2 Part B program required only four dosing days compared with nine for the current standard of care, a differentiation argument that increases the probability that positive Phase 3 data would translate into commercial adoption.

For traders, each incremental piece of data that raises or lowers that probability produces a proportional repricing of the option value embedded in the shares.

Active trading horizons for clinical biotech therefore span catalyst windows of weeks to months rather than earnings cycles. For a broader view of how biotech fits within the 2026 Stocks Market Outlook, sector rotation dynamics and rate-environment context remain relevant background variables even when company-specific catalysts are the primary driver.

Valuation & peers

Multiples vs peers + third-party analyst targets

Peer Valuation Comparison

How this stock trades versus comparable listed companies on trailing valuation multiples.

Company	Market cap	P/E	P/S
Apogee Therapeutics, Inc. · APGE	$8.4B	—	—
CG Oncology Inc. · CGON	$6.6B	—	1052.8x
Centessa Pharmaceuticals plc · CNTA	$6.3B	—	—
Xenon Pharmaceuticals Inc. · XENE	$5.8B	—	—
Celcuity Inc. · CELC	$4.3B	—	—
Legend Biotech Corporation · LEGN	$3.7B	—	2.9x

Third-party ratios (FMP), trailing twelve months. Multiples vary by data window; a negative or absent P/E means the company is loss-making. Not investment advice.

Analyst Price Targets

Hold

Wall Street sell-side analysts’ consensus 12-month price target and rating for this stock.

Consensus target

$130.92-3.0%

Target range

$89.00 – $140.00

Price-target coverage

8 analysts

Analyst ratings (14)

Buy 2Hold 12Sell 0

Targets by firm

Latest target from each of the 10 firms whose call was reported in the past 180 days. Each row links to the report.

Firm	Target	vs current
Truist Financial2026-08-13 · TheFly	$135.00	+0.0%
Stifel Nicolaus2026-06-24 · TheFly	$135.00	+0.0%
Mizuho Securities2026-06-24 · StreetInsider	$135.00	+0.0%
RBC Capital2026-06-23 · TheFly	$135.00	+0.0%
UBS2026-06-23 · TheFly	$135.11	+0.1%
Deutsche Bank2026-06-22 · TheFly	$135.00	+0.0%
Craig-Hallum2026-06-22 · TheFly	$135.11	+0.1%
Goldman Sachs2026-05-28 · TheFly	$89.00	-34.1%
Wedbush2026-05-27 · TheFly	$135.00	+0.0%
Redburn Partners2026-05-01 · TheFly	$140.00	+3.7%

Source: aggregated sell-side analyst consensus · as of 2026-08-30. These are third-party analyst opinions — not CoinUnited’s view, not a price prediction, and not investment advice.

Scenario calculator

Pick a third-party reference level and see what it implies at leverage. Reference levels only - not a CoinUnited forecast.

Scenario price

$135.09

+0.0% vs current

Your margin (USD)Leverage

Position size $100,000.00

P&L at this scenario (long)

+$0.00

Loss if liquidated -$1,000.00 (the full margin)

Liquidation price (long): $133.74 — a move of -1.0%

Trade APGE

Simplified: excludes fees, funding and slippage. Reference levels are third-party marks (CoinUnited daily kline; aggregated sell-side analyst targets), not forecasts. Leverage magnifies losses as much as gains - at high leverage a small adverse move liquidates the position. Not investment advice.

Catalysts & news

Dated third-party developments · newest first

Catalyst Timeline

Dated third-party developments that move the stock — newest first, each classified bullish or bearish and linked to its source.

2026-11-09
Next quarterly earnings◆ Scheduled
Next scheduled quarterly earnings report (2026-11-09). Revenue, margins and guidance are the near-term driver; the outcome is not known in advance.
Finnhub
2026-06-22
AbbVie confirms $10.9B Apogee purchase▲ Bullish
June 22 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday it would buy Apogee Therapeutics (APGE.O), opens new tab for $10.9 billion, the company's largest buyout in more than five years, as it seeks to bolster its treatment…
Reuters
2026-06-22
AbbVie agrees to buy Apogee▲ Bullish
AbbVie Inc. agreed to buy Apogee Therapeutics Inc.
Bloomberg
2026-06-22
AbbVie to buy Apogee for $10.9B▲ Bullish
# AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion ... AbbVie ABBV -0.95%decrease; has agreed to buy Apogee Therapeutics for about $10.9 billion to bolster the pharmaceutical company’s core immunology franchise.
The Wall Street Journal
2026-06-22
AbbVie to buy Apogee for $10.9B▲ Bullish
AbbVie to Buy Apogee Therapeutics for $10.9 Billion Bloomberg Intelligence's Sam Fazeli discusses AbbVie's $10.9 billion acquisition of Apogee Therapeutics.
Bloomberg
2026-06-19
AbbVie nears $10.9B Apogee acquisition deal▲ Bullish
June 19 (Reuters) - AbbVie (ABBV.N) is nearing a deal to acquire inflammatory disease drug developer Apogee Therapeutics (APGE.O) for about $10.9 billion in cash, the Financial ‌Times reported on Friday, citing people familiar with the…
Reuters
2026-06-19
AbbVie nearing Apogee acquisition▲ Bullish
AbbVie Inc. is nearing a deal to buy Apogee Therapeutics Inc.
Bloomberg
2026-05-27
Apogee posts positive eczema trial results▲ Bullish
May 27 (Reuters) - Apogee Therapeutics (APGE.O) on Wednesday posted favorable results from a mid-stage trial of its experimental eczema drug and secured a financing deal worth up to $1.3 billion with Blackstone Life Sciences.
Reuters
2026-05-27
Apogee posts positive eczema trial results▲ Bullish
On Wednesday, Apogee Therapeutics announced positive outcomes from a mid-phase study of its investigational eczema treatment and finalized a funding agreement potentially valued at1.
Reuters

Machine-readable table — same developments, with source

Recent third-party developments classified bullish / bearish for the stock; verbatim, sourced.

Date	Development	Direction	Source
2026-11-09	Next scheduled quarterly earnings report (2026-11-09). Revenue, margins and guidance are the near-term driver; the outcome is not known in advance.	◆ Scheduled	Finnhub
2026-06-22	June 22 (Reuters) - AbbVie (ABBV.N), opens new tab said on Monday it would buy Apogee Therapeutics (APGE.O), opens new tab for $10.9 billion, the company's largest buyout in more than five years, as it seeks to bolster its treatment…	▲ Bullish	Reuters
2026-06-22	AbbVie Inc. agreed to buy Apogee Therapeutics Inc.	▲ Bullish	Bloomberg
2026-06-22	# AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion ... AbbVie ABBV -0.95%decrease; has agreed to buy Apogee Therapeutics for about $10.9 billion to bolster the pharmaceutical company’s core immunology franchise.	▲ Bullish	The Wall Street Journal
2026-06-22	AbbVie to Buy Apogee Therapeutics for $10.9 Billion Bloomberg Intelligence's Sam Fazeli discusses AbbVie's $10.9 billion acquisition of Apogee Therapeutics.	▲ Bullish	Bloomberg
2026-06-19	June 19 (Reuters) - AbbVie (ABBV.N) is nearing a deal to acquire inflammatory disease drug developer Apogee Therapeutics (APGE.O) for about $10.9 billion in cash, the Financial ‌Times reported on Friday, citing people familiar with the…	▲ Bullish	Reuters
2026-06-19	AbbVie Inc. is nearing a deal to buy Apogee Therapeutics Inc.	▲ Bullish	Bloomberg
2026-05-27	May 27 (Reuters) - Apogee Therapeutics (APGE.O) on Wednesday posted favorable results from a mid-stage trial of its experimental eczema drug and secured a financing deal worth up to $1.3 billion with Blackstone Life Sciences.	▲ Bullish	Reuters
2026-05-27	On Wednesday, Apogee Therapeutics announced positive outcomes from a mid-phase study of its investigational eczema treatment and finalized a funding agreement potentially valued at1.	▲ Bullish	Reuters

Viktige punkter

•APGE is a binary-event stock: individual clinical readouts or regulatory interactions can move the share price dramatically in a single session, making position-sizing discipline more important than directional conviction.
•As a pre-revenue or early-revenue biotech, traditional valuation multiples (P/E, EV/EBITDA) are not applicable; cash runway, R&D burn rate, and risk-adjusted net present value of the pipeline are the relevant analytical frameworks.
•The antibody therapeutics space in immunology and inflammation is highly competitive, with large-cap incumbents and well-funded peers pursuing overlapping targets, differentiation at the mechanism-of-action level is the key moat metric to monitor.
•Institutional ownership concentration and insider activity (SEC Forms 3, 4, 5) are leading indicators of sentiment shifts for smid-cap biotechs like APGE, often signaling upcoming capital raises or partnership discussions before press releases.
•Clinical-stage biotechs with strong management teams and clean balance sheets historically attract acquisition interest from large pharma, making APGE's cash position and data package a dual-purpose asset for both independent development and M&A optionality.

Ownership

Top institutional holders (SEC Form 13F)

Top Institutional Holders

SEC 13F

The largest institutional shareholders, from SEC Form 13F filings — who holds the stock and how much.

Institution	Shares	Value
FMR LLC	9.3M	$779.6M
Venrock Adviser, LLC	8.5M	$714.9M
Wellington Management Group LLP	4.4M	$368.3M
BlackRock, Inc.	4.1M	$343.9M
Rtw Investments, LP	2.8M	$234.2M
Vanguard Capital Management LLC	2.5M	$210.6M
Janus Henderson Group PLC	2.4M	$198.8M
State Street Corp.	2.2M	$182.1M
Driehaus Capital Management LLC	1.9M	$161.7M
Perceptive Advisors LLC	1.5M	$129.7M

Source: SEC Form 13F filings · 225 institutional holders · as of 31-MAR-2026. 13F data is quarterly and lagged (filed ~45 days after quarter-end) and covers US institutional managers (>$100M AUM) only — not insiders, retail, or foreign holders. Not investment advice.

Understand the risks

Read before trading

Trading Risks

An honest, up-front list of the risks — both out of respect for the trader and as a YMYL compliance requirement.

Leverage / Liquidation

High leverage means a small adverse move can trigger forced liquidation and loss of your full margin.

High-valuation volatility

A high P/E stock is very sensitive to interest-rate and narrative shifts; swings can be large.

Session gaps

After-hours and weekend gaps; extended-hours liquidity is thinner than the regular session.

Basis risk

The CFD reference price can diverge from the exchange execution price.

Earnings volatility

Price swings widen around earnings dates and other scheduled disclosures.

Regulatory / event

Recalls, policy changes, or company-specific events can cause sharp moves.

Reference

FAQ & glossary

Ofte stilte spørsmål

Apogee Therapeutics is a clinical-stage biotechnology company developing antibody-based therapies for immune and inflammatory diseases. Its pipeline is built around validated immunology targets, with lead programs designed to potentially offer best-in-class or differentiated profiles compared with existing approved therapies. The company's scientific focus centers on pathways relevant to conditions such as atopic dermatitis, asthma, and related type 2 inflammatory diseases, a therapeutic area with substantial commercial precedent established by approved biologics. Apogee's approach emphasizes antibody engineering intended to improve upon earlier-generation molecules in terms of dosing convenience, half-life, or potency. Because APGE has no approved products and no commercial revenue, its equity value is almost entirely a function of clinical progress, probability-adjusted peak sales assumptions, and the competitive positioning of its pipeline assets. Investors and traders tracking this name typically monitor pipeline stage updates, proof-of-concept data, and any partnership or licensing activity as the primary value drivers.

Ordliste

Sentrale begreper for børsnoterte aksjer og CFD-er, ett per linje, slik at siden blir entydig både for lesere og for AI-svarmotorer.

Aksje-CFD	En differansekontrakt på en aksjekurs: kun priseksponering, ikke eierskap til de underliggende aksjene.
Utvidede handelstider	Handel før åpning og etter stenging, utenfor børsens ordinære sesjon.
Basisrisiko	Risikoen for at CFD-ens referansepris og børsens sluttpris ikke beveger seg i takt.
P/E	Pris/fortjeneste = aksjekurs / fortjeneste per aksje; et vanlig verdsettelsesmål.
Bruttomargin	Bruttofortjeneste / inntekter; gjenspeiler lønnsomheten på produktnivå.
Fortjeneste per aksje	Fortjeneste per aksje = nettoresultat / utvannet antall utestående aksjer.

symbol

APGE

Markeder

Aksjer

CU-produktkode

APGE

Source Map

Every figure on this page traces to a primary or named third-party source. "As of" dates the source; "last checked" dates our most recent read of it.

Every figure here is also published as machine-readable data, and re-checked on a schedule so a stale one shows up as stale. View the raw data

Field	Value	Source	As of	Last checked
Reference price	live	CoinUnited stock CFD reference (live)	—	—	—
52-week range	$130.34 – $232.80	CoinUnited daily kline	—	2026-08-30	—
Next earnings	2026-11-09	Finnhub	—	2026-08-30	—
Net income	$-86M	SEC 10-Q	Q2 2026	2026-08-30	View
Diluted EPS	$-1.14	SEC 10-Q	Q2 2026	2026-08-30	View
Institutional ownership	10 top holders	SEC Form 13F	31-MAR-2026	2026-08-30	View
Analyst price targets	$130.92 consensus	Aggregated sell-side analyst consensus	2026-08-30	2026-08-30	—
Peer valuations	6 peers	Third-party ratios (FMP), trailing twelve months	2026-08-30	2026-08-30	—
CoinUnited product	Stock CFD — price exposure, not equity (no voting; dividends reflected as adjustment); leverage available, extended/24h	CoinUnited product terms	—	2026-08-30	—

Om Forfatteren

CoinUnited.io Research Team

This Apogee Therapeutics, Inc. page is compiled by CoinUnited.io's research team: analysts covering listed equities and global markets, working from primary filings and named third-party data rather than opinion.

Vår Forskningsmetodikk

Every figure is traced to a primary or named third-party source and dated: financial statements from the company’s SEC filings, institutional ownership from Form 13F, analyst targets from aggregated third-party coverage, and market data from the CoinUnited reference price. The Source Map on this page lists each one with its source and the date we last checked it.

Disclaimer: content is for informational and educational purposes only and is not personalized financial advice. A stock CFD carries significant risk and provides price exposure only, not equity ownership. Always conduct your own research and consult a qualified financial advisor.

Ansvarsfraskrivelser og referanser

Viktig risikoansvarsfraskrivelse

A CoinUnited stock CFD gives price exposure to Apogee Therapeutics, Inc. only, not equity ownership: no shareholder voting rights, no dividends, and no settlement in the underlying share.

Leverage magnifies losses as well as gains, and a position can be liquidated long before the underlying share price recovers. The underlying listing trades on exchange hours, so the reference price can gap between sessions.

Brukere bør gjennomføre egen research og rådføre seg med kvalifiserte finansielle eksperter før de tar investeringsbeslutninger. Skaperne og operatørene av denne plattformen påtar seg intet ansvar for eventuelle finansielle tap eller andre skader som kan oppstå ved å stole på den oppgitte informasjonen.

Leveraged trading is extremely risky and you may lose your entire deposit.

Metodikkoversikt

Figures on this page are compiled from primary and named third-party sources, not produced by a forecasting model. Each one carries its source and date in the Source Map above.

Financial statements: the company’s own SEC filings (10-K / 10-Q), read from XBRL
Market data: the CoinUnited reference price and daily closes
Institutional ownership: SEC Form 13F quarterly filings
Analyst targets: aggregated third-party sell-side coverage — third-party opinion, not CoinUnited’s view
Peer multiples: third-party trailing-twelve-month ratios

CoinUnited does not publish a price forecast or target for Apogee Therapeutics, Inc..

Siste metodikkgjennomgang:

Klar til å begynne å handle Apogee Therapeutics, Inc.?

Bli med tusenvis av tradere og start din Apogee Therapeutics, Inc. handelsreise i dag. Få tilgang til avanserte handelsverktøy og konkurransedyktige gebyrer.

Handle APGE/USDT Registrer deg nå

APGE

Apogee Therapeutics, Inc.

$135.09

▲+0.00%24h

24h Low24h High

$135.09$135.09

Bid

$135.02

Ask

$135.16

Trade Now

Up to 1000x leverage•Tiered fees

Live from CoinUnited.io

APGE

$135.09+0.00%

Handel nå

Naviger til andre kryptovalutaer

Hurtiglenker

Posisjonskalkulator

Apogee Therapeutics, Inc.

How to trade it

Handelsregime Status

How the APGE CFD works

Trading conditions on CoinUnited

Trading APGE CFDs on CoinUnited.io: Conditions, Strategy, and Risk Management

Platform Mechanics for APGE

Catalyst-Window Strategy

Leverage Calibration for a High-Volatility Biotech

Gap Risk and the 24/7 Mitigation

Pre-Trade Checklist for APGE CFD Positions

Klar til å handle APGE?

Key facts & how to trade

Access & Tradability Comparison

Nøkkelfakta

Pris & Markedsstruktur

Company & financials

What Is Apogee Therapeutics (APGE)?

Business Model and Financial Structure

Pipeline Structure and Therapeutic Focus

Market Classification and Trading Characteristics

Nøkkelinnsikter

Key Financials

APGE in Context: Competitive Landscape and Peer Comparison

The Mechanistic Competitive Set

Efficacy Data as a Competitive Differentiator

M&A Comparables and Acquisition Premium Context

Calibrating Relative Valuation

Why Trade APGE? Catalysts, Risks, and the Bull-Bear Framework

Tier One Catalysts: Clinical Data Readouts

Tier Two Catalysts: Regulatory and Partnership Events

Tier Three Catalyst: Acquisition Premium

Risk Framework

The Optionality Framework

Valuation & peers

Peer Valuation Comparison

Analyst Price Targets

Targets by firm

Scenario calculator

Catalysts & news

Catalyst Timeline

Viktige punkter

Ownership

Top Institutional Holders

Understand the risks

Trading Risks

Reference

Ofte stilte spørsmål

1. What does Apogee Therapeutics (APGE) actually do and what diseases is it targeting?

2. What are the most important upcoming clinical catalysts for APGE in 2026?

3. How much cash runway does Apogee Therapeutics have before it needs to raise more capital?

4. What is the difference between trading APGE stock and trading an APGE CFD on CoinUnited?

5. Why do clinical-stage biotech stocks like APGE move so dramatically on data readouts?

6. Who are the main institutional holders of APGE and what does insider ownership look like?

7. How does APGE compare to peers in the immunology antibody space targeting conditions like atopic dermatitis?

8. What leverage level is appropriate when trading a high-volatility biotech CFD like APGE?

9. Does APGE pay dividends, and how is that handled on a CoinUnited CFD?

10. Does APGE have a meaningful P/E ratio, and what valuation metrics actually apply to it?

11. What does APGE's balance sheet look like, and does the company carry significant debt?

12. How does APGE typically behave around earnings announcement dates?

13. What is gap risk for APGE, and how does weekend or after-hours trading affect a CFD position?

14. What is basis risk when trading an APGE CFD versus buying the stock directly on Nasdaq?

15. How does leverage and liquidation work specifically for an APGE CFD position?

16. Can traders outside the United States access APGE CFDs on CoinUnited?

17. How does short selling work for APGE on CoinUnited, and are there any borrowing constraints?

18. What role does short interest play in APGE's price behavior during catalyst events?

19. How are APGE's clinical programs structured in terms of regulatory pathway and phase progression?

20. What macroeconomic or sector-wide factors can move APGE's price independent of its own pipeline news?

Ordliste

symbol

Markeder

CU-produktkode

Tags

Source Map

Om Forfatteren

CoinUnited.io Research Team

Vår Forskningsmetodikk